Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects
 
  • Details

A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects

Journal
Giornale Italiano di Dermatologia e Venereologia
Journal Volume
151
Journal Issue
4
Pages
412-431
Date Issued
2016
Author(s)
Tsai Y.-C.
TSEN-FANG TSAI  
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84977263565&partnerID=40&md5=80569edb9e2537e1420675d26fd8efd1
https://scholars.lib.ntu.edu.tw/handle/123456789/517596
Abstract
INTRODUCTION: Biologics are increasingly used in the treatment of moderate to severe psoriasis. However, most of the pivotal studies were performed mainly in western countries. The purpose of this review article was to compare the differences of clinical trial results between Asian and Western subjects of psoriasis regarding baseline demographics, eficacy, dermatology life quality index, safety and antidrug antibodies. EVIDENCE ACQUISITION: In this review article, we searched the PubMed/Medline, ClinicalTrials.gov, and posters from main dermatologic meetings. EVIDENCE SYNTHESIS: Only randomized controlled trial results or trial results for registration purposes of etanercept, adalimumab, inliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, guselkumab, tofacitinib, and apremilast are included. CONCLUSIONS: Asian subjects were generally 15-20 Kgs lighter, with fewer psoriatic arthritis, shorter disease duration since diagnosis, and higher baseline severity compared to western subjects. Better eficacy had been found in some studies such as secukinumab, brodalumab, ixekizumab, and tofacitinib in Japanese groups. The safety in Asian trials was generally compatible with the pivotal studies, except for the occurrence of active tuberculosis in the inliximab trial in China. Additional indications of pustular and erythrodermic psoriasis are approved in Japan for some of the agents based on phase ii/iii studies. ? 2015 Edizioni Minerva Medica.
Subjects
Adalimumab; Asia; Etanercept; Inliximab; Psoriasis; Ustekinumab
SDGs

[SDGs]SDG3

Other Subjects
adalimumab; antipsoriasis agent; apremilast; biosimilar agent; brodalumab; etanercept; guselkumab; infliximab; ixekizumab; secukinumab; tofacitinib; ustekinumab; biological factor; dermatological agent; immunologic factor; Asian; clinical trial (topic); controlled clinical trial (topic); disease duration; drug efficacy; drug safety; drug synthesis; human; immunogenicity; Medline; multicenter study (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 4 clinical trial (topic); psoriasis; psoriatic arthritis; randomized controlled trial (topic); Review; systematic review (topic); Asian continental ancestry group; body weight; pathology; psoriasis; psoriatic arthritis; severity of illness index; Arthritis, Psoriatic; Asian Continental Ancestry Group; Biological Factors; Body Weight; Dermatologic Agents; Humans; Immunologic Factors; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index
Publisher
Edizioni Minerva Medica
Type
review

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science